250 related articles for article (PubMed ID: 37395242)
1. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
3. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
[TBL] [Abstract][Full Text] [Related]
4. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
5. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
7. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
8. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.
Tan HK; Teng MLP; Soh AYS; Cheo SHY; Fook-Chong S; Goh GBB; Tan CK; Wong GW; Lee GH; Chang JPE
Am J Gastroenterol; 2021 Jul; 116(7):1437-1446. PubMed ID: 33834737
[TBL] [Abstract][Full Text] [Related]
9. Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study.
Zou Y; Zhao L; Zhang J; Wang Y; Wu Y; Ren H; Wang T; Zhao Y; Xu H; Li L; Tong N; Liu F
Acta Diabetol; 2023 Feb; 60(2):225-233. PubMed ID: 36319797
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of high-density lipoprotein cholesterol in patients with decompensated cirrhosis: a propensity score matching analysis.
Cui B; Guo G; Hui Y; Wang X; Liu W; Sun C
J Clin Lipidol; 2022; 16(3):325-334. PubMed ID: 35398041
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
[No Abstract] [Full Text] [Related]
12. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
13. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
14. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
15. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
16. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.
Wang QX; Xue J; Shi MJ; Xie YB; Xiao HM; Li S; Lin M; Chi XL
Diabetes Metab Syndr Obes; 2022; 15():2311-2322. PubMed ID: 35942038
[TBL] [Abstract][Full Text] [Related]
17. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
18. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
[TBL] [Abstract][Full Text] [Related]
19. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
[TBL] [Abstract][Full Text] [Related]
20. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]